VERA THERAPEUTICS INC. - CLASS A COMMON STOCK

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09 Dec 2024 17:29:08 By Nasdaq GlobeNewswire

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

22 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer

18 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study

11 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Vera Therapeutics to Participate at Upcoming Investor Conferences

08 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Vera Therapeutics to Participate at Upcoming Investor Conferences

08 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

07 Nov 2024 07:00:01 By Nasdaq GlobeNewswire

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

29 Oct 2024 19:22:02 By Nasdaq GlobeNewswire

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

28 Oct 2024 16:37:30 By Nasdaq GlobeNewswire

Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

26 Oct 2024 18:30:00 By Nasdaq GlobeNewswire

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Oct 2024 15:05:00 By Nasdaq GlobeNewswire

Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases

02 Oct 2024 05:30:00 By Nasdaq GlobeNewswire

Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024

02 Oct 2024 05:30:00 By Nasdaq GlobeNewswire

Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024

16 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN

12 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Sep 2024 15:05:00 By Nasdaq GlobeNewswire

Vera Therapeutics to Participate at September Investor Conferences

29 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

08 Aug 2024 07:00:01 By Nasdaq GlobeNewswire